Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche Gets Reprieve On Avastin For Breast Cancer With Delay At FDA

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA extends user fee date in lieu of reaching decision on whether or not to pull the breast cancer approval for bevacizumab.
Advertisement

Related Content

Roche Plays Up Potential First-In-Class Schizophrenia Drug In R&D Review
Roche Plays Up Potential First-In-Class Schizophrenia Drug In R&D Review
FDA Official Stresses "Flexibility" On Speeding Approval Of Drugs That Truly Stand Out
FDA Official Stresses "Flexibility" On Speeding Approval Of Drugs That Truly Stand Out
Business & Finance News, In Brief
Business & Finance News, In Brief
Advisory Committee Review Will Test Whether One Trial Will Do The Trick For Bristol's Ipilimumab
Avastin Reimbursement Worry Drives Patient Petition To FDA
Avastin Breast Cancer Approval Debate Pits Clinical Benefit Versus Statistics
Avastin Breast Cancer Approval Debate Pits Clinical Benefit Versus Statistics

Topics

Advertisement
UsernamePublicRestriction

Register

PS071193

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel